Published Date: 16 Feb 2023
Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.
Read Full NewsScreening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Combination therapies remain key as multiple agents for melasma hit the market.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.
A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
1.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
4.
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer
5.
Home Screening Appeals to Women Facing Healthcare Barriers
1.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
2.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
3.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
4.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
5.
Navigating the Complexities of Esophageal Cancer Staging
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Thromboprophylaxis In Medical Settings
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation